Oppenheimer raised the firm’s price target on Regeneron to $1,050 from $950 and keeps an Outperform rating on the shares. Regeneron announced late on Friday that Eylea High Dose was approved by the FDA for the treatment of various eye diseases, an approval that had been pending since a surprise CRL by FDA in late June, the analyst tells investors in a research note. The firm is currently modeling flat to low-single digit sales growth for the Eylea franchise in 2023 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- Regeneron price target raised to $925 from $900 at Barclays
- Regeneron announces FDA approval of Eylea HD for three indications
- EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
- RBC says Regeneron news intimates high-dose Eylea approval likely